Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2015

View Archived Issues

Anti-GDF-15 MAb restores CACS-associated phenotypic and metabolic changes

First preclinical results presented for a novel HER2-targeted ADC

Researchers report development of second-generation BTK inhibitors

Hamni Pharmaceutical divulges preclinical data of HM-95573

Pharmacokinetic assessments of RG-101 in healthy volunteers and HCV patients

GSK-2330672 as a treatment for pruritus associated with primary biliary cirrhosis

Bristol-Myers Squibb offers overview of first quarter 2015

Arena discloses results from phase I trial of APD-371

NIH grants supports SomaGenics' development of NGS microRNA library technology

Spark Therapeutics gains option to license microinjector technology

CRISPR Therapeutics raises USD 64 million in Series A and B financings

Arno's AR-12 receives E.U. orphan drug status for cryptococcosis and tularemia

Epigenomics receives E.U. grant to fund development of lung cancer blood test

Polish university discloses AdFU derivatives

Washington University patent describes Abeta imaging compounds

Agios to advance third IDH mutant inhibitor AG-881 into clinical development

Infinity Pharmaceuticals reports development of PI3K inhibitors

Merck & Co. patents cathepsin K inhibitors

Aequus and Corium collaborate on transdermal products for neurological disorders

Nihon Pharmaceutical divulges adipose tissue-derived MSCs

FDA approves Raplixa powdered fibrin sealant to help control surgical bleeding

FDA clears RE-024 for clinical study

Breo Ellipta approved in the U.S. for treating asthma in adults

Acceleron and Celgene to advance luspatercept into phase III for anemia and beta-thalassemia

FDA approves Ionsys for management of acute postoperative pain

Ixinity gains first approval for hemophilia B

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...